JMP Securities analyst Jason Butler downgraded Applied Molecular Transport to Market Perform from Outperform.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on AMTI:
- Applied Molecular Transport Announces Top-line Phase 2 Results from LOMBARD Monotherapy Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis
- Applied Molecular Transport announces phase 2 results from Oral AMT-101 trial
- Applied Molecular Transport initiated with a Buy at Chardan
- Applied Molecular Transport announces FDA ODD granted to AMT-101
- Applied Molecular Transport Announces FDA Orphan Drug Designation Granted to AMT-101 for Treatment of Pouchitis